(Adnkronos) - "In oltre 50 anni di impegno, Ail ha contribuito all’avanzamento delle conoscenze ma anche, e soprattutto, al trasferimento di queste conoscenze per un’ottimale gestione dei pazienti. E mi ferisco in particolare al fatto che Ail ha contribuito a finanziare progetti di ricerca che sono andati proprio nella direzione di migliorare le conoscenze e al tempo stesso di trasferirle”. Così Alessandro Maria Vannucchi, professore di ematologia all'Università degli Studi di Firenze, direttore della SOD complessa di Ematologia dell'azienda ospedaliera universitaria Careggi di Firenze e presidente della Società italiana di ematologia sperimentale (Sies) in occasione della conferenza per i 55 anni di Ail.
Category
🗞
NewsTranscript
00:00After 50 years of commitment and perhaps more than Eil in the more specific sector of chronic myeloproliferative aneurysms, we must say that Eil has contributed in a different way to the advancement of knowledge, but also and above all to the transfer of this knowledge for the optimal management of patients.
00:23And I refer in particular to the fact that Eil has contributed to finance projects that have gone in the direction of improving knowledge and at the same time, as I said, transferring it.
00:38What does this mean? It means that Eil has financed projects that have contributed to the identification of the most common DNA mutations that occur in these subjects.
00:48Eil is working in a different way, obviously not alone, it is working to understand in large studies on high numbers of patients treated in the so-called real life, what is the impact of these new drugs in patients with chronic myeloproliferative aneurysms.
01:06And finally Eil and Gmema have been working together for a few years now to strengthen and strengthen a network among the different centers of hematology on the national territory, not only to optimize the management of patients with these diseases, but also and above all to improve molecular diagnosis.
01:28Chronic myeloproliferative aneurysms are a family of diseases, the three main forms are essential thrombocytemia, polycythemia vera and primary myelofibrosis.
01:37They are so-called chronic diseases because they have a long survival, but very different, because while essential thrombocytemia has a survival that could be considered almost similar to that of the normal population,
01:49even today, unfortunately, the average survival of patients with myelofibrosis is around 6-7 years, so this represents an extremely urgent clinical need.
01:59In recent years, there have been great progress from the point of view of drugs that have followed the discovery of mutations that have allowed the development of selective inhibitors,
02:11the so-called JEC inhibitors, which are active on the main altered mechanism in neoplastic cells.
02:17We have already approved two of these drugs in Italy, there are four approved by the FDA, which is the American body.
02:25These drugs are able to improve the symptoms of the disease, to improve the quality of life and therefore have a positive impact on the patient's history, especially personal.
02:37What is still missing, however, is the ability of these drugs to be active at the root of the disease, i.e. the so-called disease modifiers, drugs that are able to bring healing.
02:49Today healing is not achievable with drugs, in some patients with myelofibrosis it can be obtained with the transplant of stem cells.